Brought to you by 
Millennium enters five-year oncology test deal with Becton
12 Jan 2000
Executive Summary
Millennium Predictive Medicine (MPMx) has entered into a five-year deal focused on oncology with Becton. MPMx will supply clinically validated markers to BD for melanoma, cervical, breast, ovarian, uterine, prostate, and colon cancers.
Deal Industry
- Pharmaceuticals
-
In Vitro Diagnostics
- Chemistry, Immunoassay
- Molecular Diagnostics & Genetic Testing
-
Biotechnology
- Pharmacogenetics-Pharmacogenomics
-
Drug Discovery Tools
- Genomics-Proteomics
Deal Status
- Final
Deal Type
-
Alliance
- Includes Contract
- Includes Equity
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com